Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2015

View Archived Issues

Novel synthetic method for position-selective labeling of RNAs

Phylogica and the University of Queensland receive grant for macrocylic phylomer drugs

Saphris sublingual tablets launched in the U.S. for bipolar I disorder in pediatric patients

First-in-human trial of the postexposure tuberculosis vaccine H56:IC31 in healthy adults

MoA studies of potent organo-osmium compound reveal potential new anticancer strategy

Negative modulators of alpha5-containing GABA(A) receptors show rapid antidepressant action

FDA grants orphan drug designation to C2N-8E12 for progressive supranuclear palsy

PhaseRx selects lead program to advance into clinic for orphan liver disease indication

Recro Pharma reports positive phase II data for Dex-IN in postsurgical pain

Altamira Bio acquires NIH license and CRADAs for ManNAc

ETC-159 begins phase I study in Singapore for advanced solid tumors

Merck & Co. discloses ERK2 inhibitors

Asana BioSciences presents P2X3 and/or P2X2/3 antagonists

Gilead patents MAP3K5 inhibitors

Calitor introduces JAK inhibitors

ArmaGen opens enrollment in phase I study of AGT-181 for MPS I

Bayer initiates phase I trial of BAY-1143269 with docetaxel for advanced solid tumors

Purdue Pharma patents morphinan analogs

Aquinnah Pharmaceuticals receives ALS Association funding to target TDP-43

Viekira Pak receives FDA orphan drug designation for hepatitis C in pediatric patients

Anti-MMP-9 MAb wins U.S. orphan drug designation for gastric cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...